<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03427242</url>
  </required_header>
  <id_info>
    <org_study_id>FDZL-BTA</org_study_id>
    <nct_id>NCT03427242</nct_id>
  </id_info>
  <brief_title>Apatinib for Advanced Biliary Carcinoma</brief_title>
  <official_title>A Phase II Study of Apatinib Treatment for Advanced Biliary Tract Carcinoma After Failure of the First-line Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II open-label, one-arm, single-center study of apatinib for eligible patients
      with advanced biliary tract carcinoma after the first-line treatment failure. A total of 55
      patients is planned for enrollment. The time for enrollment is from Nov 2017 to Nov 2020, the
      the follow-up will be ended after Nov 2021. Patients in the study would receive oral apatinib
      500-750mg qd until progression of disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>apatinib</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>from the time signing of ICF until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months</time_frame>
    <description>progression free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>from the time signing of ICF until the date of death from any cause, assessed up to 48 months</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Biliary Tract Neoplasms</condition>
  <arm_group>
    <arm_group_label>treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral apatinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>oral apatinib 750mg qd</description>
    <arm_group_label>treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients age between 18 and 70 years

          2. Histologically confirmed advanced biliary tract carcinoma (BTC) or metastatic BTC

          3. Prior lack of response or intolerance to at least one chemotherapeutic regimens
             (including gemcitabine).

          4. At least one measurable lesion as defined by RECIST 1.1

          5. An Eastern Cooperative Oncology Group performance status of 0 to 2

          6. Life expectancy ≥ 12 weeks

          7. For those who received other anti-tumor treatment, the damage should have been
             restored, with the time interval from last dose of nitroso or mitomycin≥6 weeks and
             interval from last dose of other cytotoxic drugs, radiation or surgery (the wound
             should be healed completely) ≥4 weeks.

          8. Acceptable hematologic, hepatic, and renal function within 7 days from screening： the
             blood ANC count≥1.5x109 /L; hemoglobin ≥ 9.0 g/dl，the blood platelet count≥80 x109 /L,
             total bilirubin &lt; 1.5 x ULN, ALT and AST&lt; 2.5 x ULN(&lt; 5 x ULN for patients with live
             metastasis), serum creatinine≤1 x ULN，endogenous creatinine clearance rate &gt;50ml/min

          9. Women of reproductive age need to take effective contraceptive measures

        Exclusion Criteria:

          1. With other malignant tumor in 5 years，except for cured cervical carcinoma in situ or
             basal cell carcinoma.

          2. Uncontrolled blood pressure on medication (140/90 mmHg); patients with &gt; Grade 1
             coronary heart disease, cardiac arrhythmias or cardiac dysfunction

          3. Symptomatic brain or meningeal metastasis

          4. History of uncontrolled seizures, central nervous system dysfunction or mental
             disorder

          5. Uncontrolled pleural or peritoneal effusion

          6. Undergoing dialysis

          7. Severe or uncontrolled infection

          8. With multiple factors that affecting oral administration

          9. Abnormal coagulation function or those receiving thrombolytics or anticoagulants

         10. Patients with tendency of gastrointestinal hemorrhage, including active peptic ulcer
             with fecal occult blood ++, hematemesis or melena within 3 months

         11. Participation in other drug clinical trials within 4 weeks

         12. Weight below 40kg

         13. urine protein ≥2+
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weijian Guo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chenchen Wang, MD</last_name>
    <phone>+8613774232040</phone>
    <email>wccnancy2003@aliyun.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chenchen Wang, MD</last_name>
      <phone>+8613774232040</phone>
      <email>wccnancy2003@aliyun.com</email>
    </contact>
    <investigator>
      <last_name>Weijian Guo, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Cereda S, Belli C, Rognone A, Mazza E, Reni M. Second-line therapy in advanced biliary tract cancer: what should be the standard? Crit Rev Oncol Hematol. 2013 Nov;88(2):368-74. doi: 10.1016/j.critrevonc.2013.05.010. Epub 2013 Jun 17. Review.</citation>
    <PMID>23786845</PMID>
  </reference>
  <reference>
    <citation>Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010 Apr 8;362(14):1273-81. doi: 10.1056/NEJMoa0908721.</citation>
    <PMID>20375404</PMID>
  </reference>
  <reference>
    <citation>Li J, Qin S, Xu J, Guo W, Xiong J, Bai Y, Sun G, Yang Y, Wang L, Xu N, Cheng Y, Wang Z, Zheng L, Tao M, Zhu X, Ji D, Liu X, Yu H. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol. 2013 Sep 10;31(26):3219-25. doi: 10.1200/JCO.2013.48.8585. Epub 2013 Aug 5.</citation>
    <PMID>23918952</PMID>
  </reference>
  <reference>
    <citation>Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R, Wang Z, Wang Q, Ouyang X, Yang Y, Ba Y, Liang J, Lin X, Luo D, Zheng R, Wang X, Sun G, Wang L, Zheng L, Guo H, Wu J, Xu N, Yang J, Zhang H, Cheng Y, Wang N, Chen L, Fan Z, Sun P, Yu H. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. J Clin Oncol. 2016 May 1;34(13):1448-54. doi: 10.1200/JCO.2015.63.5995. Epub 2016 Feb 16.</citation>
    <PMID>26884585</PMID>
  </reference>
  <reference>
    <citation>Peng H, Zhang Q, Li J, Zhang N, Hua Y, Xu L, Deng Y, Lai J, Peng Z, Peng B, Chen M, Peng S, Kuang M. Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma. Oncotarget. 2016 Mar 29;7(13):17220-9. doi: 10.18632/oncotarget.7948.</citation>
    <PMID>26967384</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2018</study_first_submitted>
  <study_first_submitted_qc>February 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2018</study_first_posted>
  <last_update_submitted>February 2, 2018</last_update_submitted>
  <last_update_submitted_qc>February 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Weijian Guo</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>biliary tract carcinoma</keyword>
  <keyword>apatinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

